Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Quantitative comparison of aflatoxin B
1
serum albumin adducts in humans by isotope dilution mass spectrometry and ELISA
Cancer Epidemiology Biomarkers and Prevention, Volume 15, No. 4, Year 2006
Notification
URL copied to clipboard!
Description
Metabolic activation of the hepatocarcinogenic mycotoxin aflatoxin B1 (AFB1) results in the covalent attachment of AFB1 to serum albumin. Digestion of adducted albumin releases AFB1-lysine, a biomarker of exposure status. AF-albumin adducts have been most frequently measured in precipitated serum albumin using an immunoassay (ELISA); however, a sensitive and specific isotope dilution mass spectrometric (IDMS) assay for measurement of AFB1-lysine in serum has recently been developed. The ELISA and IDMS methods were compared using 20 human sera collected in Guinea, West Africa, where AF exposure is endemic. Measurement of AFB1-lysine adduct concentrations by IDMS in serum and albumin precipitated from the same sample revealed that precipitation has no effect on the measured adduct levels. The concentration of AF-albumin adducts measured by ELISA and AFB1-lysine measured by IDMS in 2 mg of albumin were well correlated (R = 0.88, P < 0.0001); however, AF-albumin adduct concentrations measured by ELISA were on average 2.6-fold greater than those of the AFB1-lysine adduct. Although these data suggest that the ELISA is measuring other AF adducts in addition to AFB1-lysine, these biomarkers are comparable in their ability to assess AF exposure at AF-albumin concentrations ≥3 pg AFB1-lysine equivalents/mg albumin. Identification of other adducts may clarify the mechanistic basis for using AF-protein biomarkers to assess exposure status in future epidemiologic studies of liver cancer. Copyright © 2006 American Association for Cancer Research.
Authors & Co-Authors
Scholl, Peter F.
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
Turner, Paul Craig
United Kingdom, Leeds
University of Leeds, School of Medicine
Sutcliffe, Anne E.
United Kingdom, Leeds
University of Leeds, School of Medicine
Sylla, Abdoulaye
Guinea, Guinea
Institut Pasteur de Guinée
Diallo, Mamadou Sailou
Guinea, Guinea
Institut Pasteur de Guinée
Friesen, Marlin D.
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
Groopman, John D.
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
Wild, Christopher Paul
United Kingdom, Leeds
University of Leeds, School of Medicine
Statistics
Citations: 62
Authors: 8
Affiliations: 3
Identifiers
Doi:
10.1158/1055-9965.EPI-05-0890
ISSN:
10559965
Research Areas
Cancer
Noncommunicable Diseases
Study Approach
Quantitative
Study Locations
Multi-countries
Guinea